JPRN-UMIN000006079已完成未知
A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib - A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib
Yamagata University School of Medicine0 个研究点目标入组 44 人开始时间: 2011年7月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Inappropriate patients for this study judged by the physicians
研究者
相似试验
进行中（未招募）
不适用
Clinical trial of first line treatment with carboplatin and paclitaxel plus bevacizumab for advanced ovarian cancer patients.advanced ovarian cancerMedDRA version: 15.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003043-29-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
已完成
不适用
Retrospective analysis of patients with stage IV non-squamous lung cancer with and without TTF-1- and KRAS-G12-mutatioC34Malignant neoplasm of bronchus and lungDRKS00023890Krankenhaus Martha-Maria Halle-Dölau207
已完成
不适用
Observational cohort study in patients with severe asthma based on clinical phenotypesBronchial asthmaJPRN-UMIN000003254Division of Respiratory Medicine, Department of Internal Medicine, Hokkaido University Graduate School of Medicine300
招募中
3 期
A Randomised Phase III Study of Elacytarabine vs. Investigator’sChoice in Patients with Late Stage Acute Myeloid LeukaemiaRelapsed / refractory AMLCancer - Leukaemia - Acute leukaemiaACTRN12611000474954Clavis Pharma ASA350
招募中
3 期
Phase III confirmatory study of in patients with venous malformation, lymphatic malformation and Klippel-Trenaunay SyndromeVenous malformation, Lymphatic malformation, Klippel-Trenaunay SyndromeJPRN-jRCT2041230064Hideki Kawabata32